Credit: Shutterstock. The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum ...
Gout patients frequently have a number of comorbidities, including obesity, hypertension, high serum lipid and cholesterol levels, kidney disease, diabetes, and cardiovascular disease. [2,7,19–21] Due ...
Although these lesions are typically a late feature of gout, gouty tophi occasionally present early in the course of disease, either as the initial manifestation of gout or within a few years of first ...
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Hosted on MSN
Arthrosi gains $153m for development of gout therapy
US-based biotechnology company Arthrosi Therapeutics has completed a series E funding round, amassing $153m which is earmarked to advance the clinical development of its flagship programme, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback